. 2021 Sep 24;101(1):69–79. doi: 10.1007/s00277-021-04644-3

Table 3.

Clinical and lab characteristics of severe COVID-19 haematological cases

Variable	All pts (n = 89)	Survivor (n = 41)	Non-survivor (n = 48)	p value
Age, years
Median (range)	56(4–83)	58(4–80)	52(15–83)	0.96
Type of haematological cancer; N (%)
Acute myeloid leukaemia Acute lymphoblastic leukaemia Non-Hodgkin’s lymphoma Hodgkin’s lymphoma Multiple myeloma Chronic myeloid leukaemia CLL Post stem cell transplant	8(25) 18(21.1) 30(66.7) 1(25) 12(33.4) 5(20) 9(71.5) 6(75)	03(37.5) 07(38.9) 12(40) 01(100) 05(41.7) 04(80) 07(77.7) 02(33.3)	05(62.5) 11(61.1) 18(60) 0 07(58.3) 1(20) 02(22.2) 04(66.7)	0.12 0.29 0.10 0.21 0.18 0.11 0.19 0.17
Duration of COVID symptoms; N (%)
< 7 days ≥ 7 days	24 (27) 65 (73)	21(87.5) 20 (30.8)	03(21.5) 45 (69.2)	0.04
ECOG performance status; N (%)
< 2 ≥ 2	63(69.8) 26(29.2)	31(49.2) 10(38.5)	32(50.8) 16(61.5)	0.12
qSOFA score at ICU admission; N (%)
< 2 ≥ 2	50(18.2) 39(81.8)	33(66) 08(20.5)	17(34) 31(79.5)	0.04
Time from last chemotherapy; N (%)
< 4 weeks > 4 weeks	43 (48.3) 46(51.7)	23(53.5) 18(39.1)	20(46.5) 28(60.9)	0.67
Status of haematological malignancy at COVID-19 diagnosis; N (%)
Remission Active disease	16(18) 73(82)	3(18.7) 38(52.1)	13(81.3) 35(47.9)	0.07
Pre-existing co-infections; N (%)
Bacterial Fungal	37(41.6) 16(18)	06(16.2) 04(25)	31(83.8) 12(75)	0.03 0.05
CT severity index at ICU admission; N (%)				-
< 10 10–15 16–20 > 20	4(4.5) 53(59.1) 24(27.3) 8(9.0)	4(100) 28(66) 8(41.7) 1(12.5)	0 25(34) 16(58.3) 7(87.5)
Laboratory findings, median (IQR)
WBC Neutrophils NLR Absolute lymphocyte count Platelets Hb D-dimer Procalcitonin CRP Serum ferritin Serum fibrinogen	8250(3000–33,825) 2100(1150–5450) 3.46(0.488–22.125) 1100(900–2100) 89(27–140) 8.25(6.87–10.55) 765(338.5–1900) 3.37(0.23–7.185) 46.5(22.75–130) 1700(577–3712) 393(321–472.5)	8400(3000–33,500) 2000(1600–3600) 0.5(0.25–17.0) 800(450–1500) 91(25–149) 9(7.7–10.7) 400(249–860) 0.25(0.12–4.24) 23(9–85) 970(507–1940) 393(301–467)	8100(1000–34,800) 4100(200–5600) 8.5(3–27.5) 350(150–850) 85(48–137) 7.3(6.5–10.5) 1200(670–2200) 4.44(2.51–11.59) 128(96–186) 2492(725–6128) 392(355–490)	0.87 0.84 0.05 0.03 0.92 0.30 0.02 0.005 0.001 0.08 0.81
Treatment; N (%)
Steroids Remdesivir Convalescent plasma LMWH Tociluzumab Mechanical ventilation	89(100) 89(100) 40(45) 68(76.4) 8(9.0) 38(42.7)	41(90.1) 41(100) 18(54.5) 38(72.7) 2(9.0) 02(18.2)	48(100) 48(100) 22(36.3) 30(81.8) 6(9.0) 36(100)	0.306 0.84 0.99 0.611 0.11 0.001

Variable

All pts
(n = 89)

Survivor
(n = 41)

Non-survivor
(n = 48)

p value

Age, years

Median (range)

56(4–83)

58(4–80)

52(15–83)

0.96

Type of haematological cancer; N (%)

Acute myeloid leukaemia

Acute lymphoblastic leukaemia

Non-Hodgkin’s lymphoma

Hodgkin’s lymphoma

Multiple myeloma

Chronic myeloid leukaemia

CLL

Post stem cell transplant

8(25)

18(21.1)

30(66.7)

1(25)

12(33.4)

5(20)

9(71.5)

6(75)

03(37.5)

07(38.9)

12(40)

01(100)

05(41.7)

04(80)

07(77.7)

02(33.3)

05(62.5)

11(61.1)

18(60)

07(58.3)

1(20)

02(22.2)

04(66.7)

0.12

0.29

0.10

0.21

0.18

0.11

0.19

0.17

Duration of COVID symptoms; N (%)

< 7 days

≥ 7 days

24 (27)

65 (73)

21(87.5)

20 (30.8)

03(21.5)

45 (69.2)

0.04

ECOG performance status; N (%)

< 2

≥ 2

63(69.8)

26(29.2)

31(49.2)

10(38.5)

32(50.8)

16(61.5)

0.12

qSOFA score at ICU admission; N (%)

< 2

≥ 2

50(18.2)

39(81.8)

33(66)

08(20.5)

17(34)

31(79.5)

0.04

Time from last chemotherapy; N (%)

< 4 weeks

> 4 weeks

43 (48.3)

46(51.7)

23(53.5)

18(39.1)

20(46.5)

28(60.9)

0.67

Status of haematological malignancy at COVID-19 diagnosis; N (%)

Remission

Active disease

16(18)

73(82)

3(18.7)

38(52.1)

13(81.3)

35(47.9)

0.07

Pre-existing co-infections; N (%)

Bacterial

Fungal

37(41.6)

16(18)

06(16.2)

04(25)

31(83.8)

12(75)

0.03

0.05

CT severity index at ICU admission; N (%)

< 10

10–15

16–20

> 20

4(4.5)

53(59.1)

24(27.3)

8(9.0)

4(100)

28(66)

8(41.7)

1(12.5)

25(34)

16(58.3)

7(87.5)

Laboratory findings, median (IQR)

WBC

Neutrophils

NLR

Absolute lymphocyte count

Platelets

D-dimer

Procalcitonin

CRP

Serum ferritin

Serum fibrinogen

8250(3000–33,825)

2100(1150–5450)

3.46(0.488–22.125)

1100(900–2100)

89(27–140)

8.25(6.87–10.55)

765(338.5–1900)

3.37(0.23–7.185)

46.5(22.75–130)

1700(577–3712)

393(321–472.5)

8400(3000–33,500)

2000(1600–3600)

0.5(0.25–17.0)

800(450–1500)

91(25–149)

9(7.7–10.7)

400(249–860)

0.25(0.12–4.24)

23(9–85)

970(507–1940)

393(301–467)

8100(1000–34,800)

4100(200–5600)

8.5(3–27.5)

350(150–850)

85(48–137)

7.3(6.5–10.5)

1200(670–2200)

4.44(2.51–11.59)

128(96–186)

2492(725–6128)

392(355–490)

0.87

0.84

0.05

0.03

0.92

0.30

0.02

0.005

0.001

0.08

0.81

Treatment; N (%)

Steroids

Remdesivir

Convalescent plasma

LMWH

Tociluzumab

Mechanical ventilation

89(100)

40(45)

68(76.4)

8(9.0)

38(42.7)

41(90.1)

41(100)

18(54.5)

38(72.7)

2(9.0)

02(18.2)

48(100)

22(36.3)

30(81.8)

6(9.0)

36(100)

0.306

0.84

0.99

0.611

0.11

0.001